| Field | Specification |
|---|---|
| Target | |
| Applications | |
| Molecular weight | |
| Molecular formula | C30H50N6O13S2·xC2HF3O2 |
| Purity | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Box5 TFA is a potent Wnt5a antagonist that inhibits Wnt5a signaling and Wnt5a-mediated Ca2+ release. It also inhibits cell migration and has been studied for potential relevance to melanoma research[1]. It is supplied as a white to off-white solid (C30H50N6O13S2·xC2HF3O2, MW 766.88 (free base)) at 99.50% purity.
Physical & Chemical Properties
| Molecular Formula | C30H50N6O13S2·xC2HF3O2 |
|---|---|
| Molecular Weight | 766.88 (free base) g/mol |
| Purity | 99.50% |
| Appearance | Solid |
| Color | White to off-white |
| Sequence | t-Boc-Met-Asp-Gly-Cys-Glu-Leu |
| Sequence (one-letter) | t-Boc-MDGCEL |
| Target | Wnt5A |
| Signaling Pathway | Stem Cell/Wnt |
| Solubility | In Vitro: DMSO: 100 mg/mL (Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Sealed storage, away from moisture and light, under nitrogen. Powder: -80°C, 2 years; -20°C, 1 year. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture and light, under nitrogen; avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL; clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.5 mg/mL; clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.5 mg/mL; clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
Box5 TFA (100 μM) lowers p-MARCKS expression stimulated by rWnt5a (0.1 μg/mL) in A2058 cells[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Single-Cell RNA Sequencing Identifies MMP11+ Cancer-Associated Fibroblasts as Drivers of Angiogenesis and Bladder Cancer Progression. Adv Sci (Weinh) 2025 Aug;12(32):e02774. PMID: 40552583
Inhibition of stromal MAOA leading activation of WNT5A enhance prostate cancer immunotherapy by involving the transition of cancer-associated fibroblasts. J Immunother Cancer 2025 Mar 22;13(3):e010555. PMID: 40121032
Wnt5a/β-catenin-mediated epithelial-mesenchymal transition: a key driver of subretinal fibrosis in neovascular age-related macular degeneration. J Neuroinflammation 2024 Mar 26;21(1):75. PMID: 38532410
Nano Today. 2024 Apr, 55, 102201.
PFPeA exposure drives hepatoxicity and liver fibrosis via oxidative stress/Wnt5a-induced hepatocyte senescence. J Hazard Mater 2026 Feb 1:503:141085. PMID: 41529635
Single-cell and spatial transcriptome profiling reveal CTHRC1+ fibroblasts promote EMT through WNT5A signaling in colorectal cancer. J Transl Med 2025 Mar 6;23(1):282. PMID: 40050872
Dendrobine ameliorates non-alcoholic fatty liver disease by inhibiting mitochondrial fission through modulation of the Wnt5a/p-CaMKII/p-Drp1 signaling axis. J Ethnopharmacol 2026 May 23:363:121445. PMID: 41763618
Canonical Wnt signaling affects calcium homeostasis in serum-treated AC16 cells through MLN-mediated SERCA2a regulation. J Mol Cell Biol 2025 Dec 5:mjaf050. PMID: 41348974
Wnt/β-catenin pathway induces cardiac dysfunction via AKAP6-mediated RyR2 phosphorylation and sarcoplasmic reticulum calcium leakage. J Mol Cell Biol 2025 Jul 28;17(2):mjaf002. PMID: 40097291
DOCK1 inhibitor Box5 (TFA) suppresses proliferation of AML cell lines and prolongs survival in AML xenograft models. Sci Rep 2026 May 11;16(1):21377. PMID: 42108312
